Anheuser-Busch InBev/NV (BUD) Q3 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/10/31/anheuser-busch-inbevnv-bud-q3-2024-earnings-call-t/?source=iedfolrf0000001
Oct 31, 2024 - BUD earnings call for the period ending September 30, 2024.
0
Relay Stock Soars on Upbeat Data From Breast Cancer Study
https://www.zacks.com/stock/news/2334138/relay-stock-soars-on-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334138
Sep 10, 2024 - RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
0
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
https://www.zacks.com/stock/news/2334045/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334045
Sep 10, 2024 - BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
0
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
https://www.zacks.com/stock/news/2333625/travere-gains-11-on-securing-full-fda-nod-for-kidney-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333625
Sep 09, 2024 - The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
0
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
https://www.zacks.com/stock/news/2332674/novartis-to-license-vygr-s-capsid-for-gene-therapy-in-neurology?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332674
Sep 06, 2024 - NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
0
NVS or LLY: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2331584/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2331584
Sep 04, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option?
0
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
https://www.zacks.com/stock/news/2326419/alnylam-alny-amvuttra-givlaari-fuel-revenues-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2326419
Aug 23, 2024 - Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
0
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
https://www.fool.com/investing/2024/08/18/2-unstoppable-healthcare-stocks-to-buy-right-now/?source=iedfolrf0000001
Aug 18, 2024 - These companies' growth paths should only be briefly interrupted by headwinds.
0
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
https://www.zacks.com/stock/news/2323425/incyte-incy-announces-data-on-monjuvi-fda-approval-for-gvhd-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2323425
Aug 16, 2024 - Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.
0
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
https://www.zacks.com/stock/news/2319903/pharma-stock-roundup-lly-nvo-bayry-q2-earnings-mrk-s-new-deal-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2319903
Aug 09, 2024 - Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
0
Page 1>